Addiction 2002: Vol 97 Index

11 Pages·2002·2.4 MB·English

AUTHOR INDEX
300k reviewer: (C) =c ommentary; (E) = editorial; (L) = letter to the editor: (N & N) s and notes; ( supplement
\arons, G.A., 717 Brown, T.G., 67 Dahlber
\dlaf, E.M., 1583 Browne, N., 125 D' Amic«
Adnet, FE, 1295 Brugal, M.T., 319
\hluwalia, H.K., 861 Brugha, T., 1551
\hluwalia, J.S., 861 Brunelle, E., 1221 (L)
Ali, R., 771 (E) van Brussel, G.H.A., 993
Ali, R.L.. 49 3uchan, B.J., 46 (S), 98 (S)
\lmeida, O.P., 15 Bihringer, G., 295, 762 (BR
Altmann, D., 230 (L) 3urgdorf, J., 459
(Amato, L., 1241 Burleson, J.A., 35 (S), 58 (S
\nderson, B.J., 691 Burrows, S., 1449
AndersP.o, n61,9 (E), 951, 961 Buster, M.C.A., 993
\ndréasson, S., 901
Annis, H., 677 Caetano, R., 120 (N&N
Anthony, J.C., 1505( ¢ 633, 929 (E)
\ntonanzas, F., 1145 aldwell, T.M., 583
Arvers,P ., 1607 (L) allard, C., 918 (BR
Ashton, H., 756 (L) ‘alle, R., 819
\ssanangkornchai, S., 217 ‘ampana, A.A.M., 9
\ubin, H.-J... 1347 ‘arlin, J.B., 187
\woleso, N., 1611 (1 ‘arnwath
arroll,|
‘aspari
S) asswe
Badenoch édras, |
Chaikummao, S., 801
hantarujikapong, S
‘hapman 99 (J
Baker. T.B., 1093 vastra 691
Bammer,G. ,
arrio
sersabe Moran
Black, M 1517
slaszczynski, A
329
mmvist, |] 136
Bluthenthal, R.N
1003
Borland 5 onklin
on, S.W., 1295 onnell
Bowman, J.A., 1 ooper, M.1
sovs, A 1551 opeland !
Brantley, L.B., 46
Breslau, N., 1063
in den Brink, W., 993
Brinkley, A., 329
Britton, A., 230 (L)
Brers, O uljpers
Brown, J., ummings
Brown, : 7 Cunradi, (
2002 Society for the Study of Addiction to Alcohol and Other Drugs
1626 Author Index
French, M.T., 84 (S) Higley, J.D., 415 Kleiman, M.A.R., 113 (BR)
Frenk, H., 95 (L) Hill, E.M., 375 (BE), 401 Klingemann, H., 661
Fromme, K., 563 Hillbom, M., 102 (L) Knutson, B., 459
Frosch, D., 1317 Hills, A.M., 598 (L) Kolte, B., 329
Fry, C., 229 (L) Hilton, M.E., 134 Korten, A.E., 583
Funk, R., 46 (S) Hitsman, B., 785, 799 Kosaka, K., 809
Holdcraft, L.C., 1025 Koski-Jannes, A., 764 (BR)
Galliot-Guilley, M., 1295 Holder. H., 238 (BR) Kouvonen, A., 311
Garcia-Altés, A., 1145 Horowitz, J.L., 663 Kozel, N.J., 969
Garrett, R., 1329 Horwood, L.J., 1055, 1123 Krook, A.L., 533
Geater, A.F., 217 Houston, T., 959 Kuo, M., 1583
Geerlings, PJ., 1071 van den Hout, M., 87 Kuoppasalmi, K., 851
George, T.P., 795 Hughes, J.R., 111 (BR), 798, 1219 (L) Kwiatkowski, C.F., 1289
Gerald, M.S., 415 Hulse, G.K., 15, 1269
Gerstein, D.R., 1011 Humphrey, K., 891 Labouvie. E., 104]
Gilbert, D.G., 796 Humphreys, K., 126 (E), 138 Lagrue, G., 1347
Gilchrist, G., 1517 Lancrenon, S., 1347
Gill, K., 347 lacono, W.G., 1025 Landabaso, M., 819
Gilvarry, E., 329 Iraurgi, I., 819 Lange, J.E., 1195, 1
Glass, K., 1561 Isacsson, S.-O., 205 Laranjeira, R.R
Gliksman, L., 1583 Iseki, E., 809 Lawrence, D., 1
Gmel, G., 105 (L) Israel, J.A., 1215 Leccese, A.P., 7
Godley, M.D., 16 (S) Israel, Y., 483 Lechi, A., 985
Godley, S.H., 16 (S), 70 (S), 84 (S) Leclerc, P., 1003
Goldberg, J., 1137 Jackson, K.M., 517 Lee, H., 1583
Goldgran-Toledano, D., 1295 Jacomb, P.A., 583 Lee, K., 1215
Goodwin, R.D., 555 Jaffe, J.H., 1356 Legleye. S., 707 1609 (L)
Gorodetzky, C.W., 505 James, J.E., 1251, 1257 Lende, D.H., 447
Gorsline, J., 505 Jarvik, M.E., 1317 Leppanen, K., 1037
Gossop, M., 39, 169, 1259 Jenkins, R., 1551 Lessiter, J., 1163 >
Gowing, L.R., 49 Jensen, N.K., 1041 Levy, D.T., 909
Grau, L.E., 1277 Jernigan, D., 615 (E) Lewin,T. , 1329
Gray Cerbone, F., 1011 Jiménez-Lerma, J.M., 819 Lewis, G., 1551]
Greenfield, T.K., 29 Johnson, E.O., 1063 Li, C., 1305, 1537
Grenyer, B.E.S., 108 3 (E) Johnson, M.B., 1195, 1205 Li. X., 575
Grieshaber-Otto, J., 918 (BR) Johnson, R., 329 Liddle, H., 16 (S), 70 (S)
van Griesven, F., 801 Johnson, R.A., 1011 Lieber, C.S., 483, 1230 (BR)
Gripenberg, J., 901 Jolley, D.J., 1395 Lindstrém, M., 205
Gronbeek, M., 103 (L) Jones, R., 1517 Ling, W., 771 (E), 1317
Grouff, K., 533 de Jong, A., 67 Lintonen, T., 311
Gruer, L., 1517 Jonkers, R., 67 Lintzeris, N., 1395
Gueye-Guilley, M., 1295 Jorm, A.F., 583 Liu, T., 1305
Gulliver, $.B., 785, 799 Judd, A., 845 Lorente, F.O., 1609 (L)
Gutiérrez-Fraile, M., 819 Juon, H.S., 833 Lugoboni, F., 104 (L), 985, 1613 (L)
Lundborg, P., 1573
Hagen, E.H., 389 Kabela, E., 135 (S) Luz, E., Jr 9
Hahn, J.A., 1511 Kadden, R., 109 (S), 135 (S) Lynskey, M., 187, 1508 (C)
Haley, N., 1003 Kadmon-Telias, A., 1473 Lynskey, M.T., 583
Hall, W., 1 (E), 179, 243 (E), 472, 478 Kamijo, A., 809 Lyons, M.]J., 1137
(E), 665, 754 (L), 977, 1480 (BR) Kaminer, Y., 16 (S), 58 (S)
Hamilton, N., 16 (S), 46 (S) de Kan, R., 1071 Ma Olle, J., 1145
Hao, W., 1305 Kandel, D., 655 McArdle, P., 329
Hasin, D.S., 555 Kaskutas, L.A., 891 McCaffrey, D.F., 1493, 1509 (C)
Hawks, D., 763 (BR) Kaye, S., 179, 727, 977 McCarthy, D.E., 1093
Hayaki, j., 1041 Kenkel, D.S., 1505 (C) McCarthy, D.M., 717
Heather, N., 293 Kentner-Figura, B., 1593 McCarthy, S., 329
Heimer, R., 1277 Kerkhof, A.J.BM., 1071 McChargue, D.E., 785
Heinz, A., 1369 Kilmarx, P.H., 801 MacCoun, R.]J., 663
Hellebusch, S.J., 505 Kindt, M., 87 McCrady, B.S., 1041
Henn, F., 1593 King, L.A., 1531 McEwen, A., 595
Henntfield, J.E., 98 (L) Kirchmayer, U., 1241 McIlwaine, A.. 501
Hermann, D., 1369 Kishimoto, H., 809 McLean, P.C., 59
Herrell, J.M., 84 (S), 125 (S) Klatsky, A.L., 103 (L) McLelland, A.T., 249 (E)
Hickman, M., 845 Kleber, H.D., 660 McMahon, T.J., 1109, 1120
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 1625-1628
Author Index 1627
McNeil, D.R., 217 Okudaira, K., 809 Roysamb, E., 5
MacNeill Horton, A., Jr 1 (S) Oliveira Soares, B.G., 931 Roberts, K., 845
MacPhee, D., 243 (E) Oliver, J., 1517 Robertson, S.1., 1269
McRee, B., 125 (S) Oliviera, E.M., 9 Rodgers, B., 583
McSweeney, T., 845 Oncken, C., 745 Roebuck, M.C., 4 (S), 16 (S)
Magnus, P., 533 Orford, J., 600 (L), 1361 (E) 84 (S)
Makela, P., 701 Osterberg, E., 606 (BR) Roffman, R.A., 135 (S)
Maksad, J., 691 Rogers, J.D., 29
Mallonee, S., 909 Pach, A., Hf 1011 Rolf, C.N., 505
Mann, K., 1369 Paddock, $.M., 1493, 1509 (C) Romano, E.O., 909
Mann, R.E., 1237 (E) Paisecki, T.M., 1093 Romelsjé, A., 915 (L)
Manopaiboon, C., 801 Pajusco, B., 1613 (L) Room, R., 1256
Manski, C.F., 663 Panksepp, J., 459 Roozen, H.G., 1071
Marlatt, A., 607 (BR) Paraherakis, A., 347 Rosenberg, H., 59
Marsden, J., 39, 169, 77 Parke, R.D., 1118 Ross, J., 977, 1383
1551 Parna, K., 871 Rossler, W., 1593
Marsh, A., 1339 Parry, C.D.H., 969 Rossow, I., 363 (BR), 1228 (BR)
Marshall, P.A., 1277 Parsons, J., 845 Rotherham-Fuller, E., 1317
Martin, B.R., 754 (L) Pates, R., 1077 (BR) Rotily, M., 1221 (L)
Mastro, T.D., 801 Patton, G.C., 187 Rounsaville, B.J., 1109, 1120
Matheson, C., 1405 Roy, E., 1003
Pedarriosse, A.-M., 1347
Mathios, A.D., 1505 (C Pedersen, K.M., 227 (L) Royuela, | 319
Matsumoto, T., 809 Pelzer, K., 1561 orth, L., 1395
Mattick, R.P., 1523
Pennings, J.M., 773
Maynard, A., 654
Pentz, M.A., 1537
Mazzaglia, G., 230 (L)
Pereira Reisser, A.A., 931
Megarbane, B., 1295
Peretti-Watel, P., 707, 1609 (I
Meltzer, H., 1551 Sanci, I
Perl, H.L., 134
Melville, J., 59 Perneger, T.V., 7 >>2 Sanz. |
Metrebian, N., 1155 Sarna. S.. 851
Perreira, K.M., 301
Meyer, R.E., 603 Perucci, C.A., 1241 Sarti, M., 161
Meyers, R., 70 (S) Petry, N.M., 745 Sattah, M.V., 801
Mezzelani, P., 104 (L), 985, 1613 (L) Phares, V., 1119 Saunders, J.B., 2
Michels, I., 329 Phillips, T.S., 1465 Scherrer, ].F.,
Midanik, L.T., 361 (BR) Piek, J., 1339 Schleusener, D.S., 505
Miller, M., 109 (S), 125 (S), 135 (S) Pieronlini, A., 329 Scott, C.K., 16 (S)
liller, T.R., 909 Sears ~ 1055
Pitcairn, J., 1405
Miller, W.R., 265 Pledger, M., 1427 Seymou 1517
Milne, B.J., 1055 Poikolainen, K., 1037 Shaffer, H.] 3
Miyakawa, T., 809 Shakeshaft
Poulton, R., 1055
Moffitt, T-E., 1055 Powell, J., 1163 Shatenstein, S
Moos, B.S., 75 Pratap, S., 1427 Sher, K ]
Moos, R.H., 75, 877 Preston, A., 595
Morojele, N.K., 969
Prokhorov, A.V.,
Morral, A.R., 1493, 1509 Shiffman. S..
Mosier, M.C., 861 Shoptaw, S., 1317
Quaglio, G..,
Moskalewicz, J., 133. Siegiried N., 969
Quensel, S.,
Moss, A.R., 1511 Silva de Lima, M., 931
Moyer, A., 253, 279 Simon, N.G., 15
Rabe-Hesketh, S., 825 Singer, M
Nahom, D., 1317 Rahu, K., 871 Singleton
Naukkarinen, H., 851 Rahu, M., 871 Sloan, I
Nazir, N., 861 Rames, A., 1347 Sly, K., 1
Negrete, J.C., 1481 (BR) Ramos, S.P., 9 Smart, R.G., 107
Nemtsov, A.V., 1413 Rawson, R.A., 1317 Smith, E.0., 447
Nesse, R.M., 470 Regidor, E., 319 Smith, G.S., 909
Newlin, D.B., 375 (E), 427 Rehm, J., 29, 105 (L), 14 BR Smith, L., 1339
Niaura, R., 357 (L) Reichler, H., 1329 Smith, N., 916 (L)
Nichol, A.C., 75 Requiao, D.H., 9 Smith, N.T., 621
Nizzoli, U., 1365 Reuter, P., 653 Solowij, N., 1083 (E)
Nower, L., 487 Reymann, G., 601 (L) Spicer, R.S., 909
Richter, K.P., 861 Spooner, C., 478 (E)
Ochoa, K.C., 1511 Ricordel, I., 1295 Sprivulis, P., 1269
Ojesj6, L., 133 Rist, F, 115 (BR) Stamm, K., 1593
2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 1625-1628
1628 Author Index
Stanton, B., 575 Terry, M., 1329 Weatherburn, D., 657
Stein, M.D., 691 Tiffany, S.T., 155, 1219 (L) Webb, C.P.M., 16 (S), 35 (S), 58 (S), 70
Steinberg, K.L., 135 (S) Timko, C., 877 (S), 84 (S)
Stephens, R.S., 109 (S) Tims, E.M., 16 (S), 46 (S), 70 (S), 84 (S), Wechsler, H., 1583
Steptoe, A., 1561 98 (S) de Weerdt, I., 67
Sterling, R.C., 294 Tippetts, A.S., 1205, 1439 Weisner, C., 763 (BR)
Sterling, S., 763 (BR) Titus, J.C., 16 (S) West, R., 1 (E), 7 (E), 98 (L), 234 (N &
Stern, G., 1593 Tober, G., 237 (BR) N), 501, 595
Stewart, D., 39, 169, 1259 Toomey. R., 1137 Westley Clark, H., 1 (S)
Stimson, G.V., 845, 1155 Tourneau, J., 1295 White, J.M., 49
Stockwell, T., 113 (BR), 1 478 (BR) rreacy, S., 39 White, W., 919 (BR)
Stoeckel, I., 329 True, W.R., 1137 White, W.L., 1087
Stolerman, I.P., 152 Tsuang, M.T., 1137 Wiegersma, A
Storz, T., 1155 Tsuda, A., 1561 Wiers, R.W., 5‘
Strang, J., 927 (E) Tucker, J.A., 126 (E), 138 Wilbourne, P.L., 2
Suchman, N.E., 364 (BR) Turnbull, P.J., 845 Willems, B., 87
Suelves, J.M., 319 Wodak, A., 240 (L)
Sullivan, R.J., 389 Ungemack, J.A., 35 (S) Wolff, K., 1229 (BR)
Sumnall, H.R., 153 de Wolff, RA.. 773
Supawitkul, S., 801 Vendetti, J., 125 (S) Wood, P.K., 517
Sutton, S., 1171 Venturini, L., 985 Wutzke, S.E., 665
Swain-Campbell, N., 112 Vergun, P., 279
Swan, G.E., 100 (L) Verster, A.D., 1241
Xian, H., 1137
Swearingen, C.E., 2 Vessicchio, J.C., 795
Xiao, S., 1305
Swift, W.. 607 (BR) Vinck, J., 1561
Voas, R.B., 1195, 1205, 1439
Tacke, U., 1355 (L) Vorma, H., 851 Yabana, T.,
Tait, R.j., 1269 Vuori, E., 1037 Yang.
Tait, S., 1163 Yang,
Talamini, G., 985 Waal, H., 533 Young, D., 1
larter, R.E., 920 (BR) Wagstaff, G.B., 1531 Young, N.I
Taylor, C., 1551 Wallin, E., 901
Taylor, D.R., 1055 Wardle, J., 1561 ZaiZn., ,96 0
Tejeiro Salguero, R.A., 1601 Warner, J., 239 (BR), 605 (BR), 1077 Zhang, D., 1305
Telias, 1.D., 1473 (BR) Zhou, Y., 575
Temblay, J., 677 Warner-Smith, M., 963 Zitman, F.G., 337
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs
SUBJECT INDEX
BR) = Book review; (C) =c ommentary; (E) = editorial; (L) = letter to the editor; (N & N) = news and notes; (S) = supplement.
\ccidents (alcohol-related RTAs), public health perspective, 6 33-645, community intervention, underage
909-914, 1439-1448 929 (E), 1621-1623 (N&O drinking, Mexico, 1205-1214
\i Idiction: social consequences, 363, (BR ce unity-based counselling
Blackwell: new publishers, 8 (E) and stroke, 102—104 (L) 31 (I 1449-1463
book prize 2001, 1076 and women, 763—764 (BR gend lifferences in help-utilization,
editorial processes under scrutiny, 610 young adults 877-889
(N&N) association with symptoms of Impaired Control Scale, 1339-1346
refereeing policy, 7 (1 depression and anxiety, 58 3-594 methodological analyse 5 3-263,
role in raising profile of research comparison between American and 65-2
ethics, 229-230 (L) Canadian college students vention activities, Equado
senior editorial staff declarations of 1583-1592 N&N
interest, 125 (E) drinking trajectories: identification toward more responsi
\dolescents see Family; Prevention and prediction, 1427-1 / 126-132 (E), 133
programmes; specific substances and educational and occupational \Icohol \nonymous
addiction problems attainment, 717-726 Alcoholism see Alcohol d
\drenergic agonists in opioid \lcohol dependence lc related violence
vithdrawal, 49-58 Alcohol Urge Questionnaires 1622 (N&N
DS see HIV/AIDS 1465-1472 \lzheimer's disease, smokinga s
lcohol dual dependence, 169-178 factor, 15-28
adolescents as evolutionary hangover, 381-3 phetamine see Metamphetamine
beyond the U-curve: relationship gender differences, cohort effects lic steroids
between sport and alcohol, 1025-1036 body-building and, 1077 (BR)
cigarette and cannabis use hypothalamic—pituitary—thyroid axis ’ h risks among gay men attending
707-716, 1607-1611 (L) dysregulation, 1 369-1381] London gyms, 195-203
cross-border drinking, Mexico, public health perspective, 633-645 \s an Pacific regior
1195-1203, 1205-1214 Research Society on Alcoholisn ilcohol consumption and advertising,
econometric analysis, 1573-1582 483-486 610-611 (N&N
multiple hospital presentations, and somatic comorbidity among lassic texts, McCoy
1269-1275 homeless, Mannheim, Germ
part-time work and heavy drinking, 1593-1600
Finland, 311-318 treatment see Alcohol treatm
Spain, 1232 (N&N) Alcohol marketing
and tobacco use: onset, persistence \bsolut: Biography of a Bottl
and trajectories, 517-531 (BR) ASSI Alcohol, Smoking and
advertising see Alcohol marketing in Asia, 610-611 (N&N Substance Involvement Screening
and alcohol-related disorders in young people, 1232-12
Germany, | }1 5-1 16 \lcohol mortality
classic texts, | 12 (BR l-cause, effects of dey ind hol-related violence, 1622 (N & N)
361-362 : ) social integration, 2 } nnabis dependence in young adults,
(BR) 915-916( 1
cocaine, ellects ncurrent use fatal poisonings
773-783 inland, 929 (E)
n disease and health, 240 (BR \ussia, 1413-1425
doctors drinking on call, 1487-1488 young Europeans 5-1 pic verd ng death rates,
N&N | | policies
irinking patterns in EU and Norway European, global ramificat
238-239 (BR
irink driving see Blood ¢
concentration (BAC
under the influence | \lcohol 1g ubstan [ hometric ition duringa
volutionary approa } Involve I eenin ntin program in
+()] 5, 415 ) ASSIST)
expectancy model, 59° ) \lcohol subtypes, classific
overlap of typo
and health outcomes: health Alcohol treatment
retirement study I } 310 brief interventions
home environment and development ong-term effecti
of use disorders lailand ta-analyti
217-226 293-294 ) ) Blood alcohol concentration (BAC)
life-history theory and risky drinking / ’) BAC-negative victims in alcohol-
$01-413 or needle exchangers RAINI involved injury accidents,
overserving, Stockholm, 901-907
002 Society for the Stud \ddictiont o Alcohol and ! t idiction, 97 29-1634
1630 Subject Index
children in fatal crashes: driver BAC economic perspectives, 84—97 (S), Community-based alcohol counselling,
and demographics, 1439-1448 1505 (C) 1449-1463
see also Driving under the influence effects on self-reported health Complementary therapies for addictions,
(DUI) measures, socio-demographics 1491-1492 (E)
Brain emotional systems, 459-469 and quality of life, twin study, Conflict of interest
BRAINE (brief alcohol interventions for 1137-1144 Addiction senior editorial staff, 125 (E)
needle exchangers), 691-700 effects of tobacco and, on lung potential, in gambling research,
Brazil function in young adults, 600-601 (L)
Association for the Study of Alcohol 1055-1061 tobacco research, 1—5 (E), 95—102 (L),
and Other Drugs (ABEAD), 9-13 gateway effect, 1493-1503, 22 229 (L). 756-758 (L),
conference, 120-121 (N & N) 1505-1510 (C) 1359-1360 (N &N)
International Harm Reduction juvenile offenders, 35-45 (S) see also Public—private partnerships
Association, conference, out-patient treatment models, 70-8 3 Coping responses, after residential
1488-1489 (N & N) (S) treatment for heroin use,
Brief interventions pre-treatment drop-out among people 1259-1267
adolescents, 563-574, 607 (BR) with dependence, | 25—1 34 (S) Cue-exposure treatments, applying
for alcohol abuse see under Alcohol psychological adjustment in extinction research and theory,
treatment adolescence and young 155-167, 357-359 (L),
long term evaluation, 619-620 (E) adulthood, 1123-1135 1219-1221 (L)
smoking cessation activities of GPs, self report, on-site urine testing and
595-597 laboratory testing, 98—108 (S) Depression
Britain tailoring dependence treatment for a and alcohol consumption, 29-38,
acceptability and availability of diverse population, 135-142 583-594, 915-916 (L)
pharmacological interventions for (S) psychometric evaluation during a
substance misuse, 59-65 treatment of use disorders, 1—3 (S), discontinuation program in
anabolic steroid use and health risks 4-15 (S) chronic benzodiazipine users in
among gay men attending Cannabis Youth Treatment (CYT), general practice, 337-345
London gyms, 195-203 1—3 (S), 16-108 (S) see also Suicide
doctors prescribing diamorphine to Marajuana Treatment Project Doctors
opiate-dependent drug users, (MTP), 109-142 (S) drinking alcohol on call, 1487-1488
1155-1161 withdrawal symptoms, 621-632, (N & N)
drug policy, 233 (N & N), 240-241 (BR) 754-756 (L), 916-917 (L) prescribing diamorphine to opiate-
addicted offenders, 365 (BR) Children dependent drug users,
smoking cessation treatment services, in fatal alcohol-related crashes, 1155-1161]
234(N&N) 1439-1448 see also General practice; Outpatient
syringe exchange, 845-850 ‘Healthy School and Drugs’ project, treatment
Buprenorphine 67-73 Driving under the influence (DUI)
abuse by intravenous injection, 1355 see also Family cross-border drinking, 1195-1203
(L) China, illicit drug use 1205-1214
in opiate dependence, 533-542, initiation, 575-582 research-based definition, 1237-12
1395-1404 prevalence rates and use patterns, (E)
1305-1315 see also Blood alcohol concentration
Cancer Cigarettes see Smoking; Smoking (BAC
cannabis use and, 243-247 (E) cessation; Tobacco industry Drug culture, risk and control in
passive smoking and, 1487 (N & N) Citation counts, and peer ratings of (SONAR Project), 363-364 (BR)
Cannabis quality, 501-504 Drug dependence
age-dependent consequences, Cocaine dual dependence, 169-178
108 3—1086 (E) alcohol and, effects of concurrent use, histories, 608-609 (BR)
beyond the U-curve: relationship 773-783 recovery, 918—920 (BR)
between sport and alcohol, determining a diagnostic cut-off for stimulus generalization and ‘web of
cigarette and cannabis use in dependence, 727-731 dependence ', 152 ] 54 (C)
adolescents, 707-716, factors associated with first treatment syphilis infection, Western Germany,
1607-1611 (L) entry and treatment re-entry, 601-602 (L)
and cancer, 243-247 (E) 825-832 WHO expert committee on, 1 359
characteristics and problems of pharmacological treatment of (N & N)
adolescent users, 46-57 (S) dependence, 931-949 Drug misuse
classifying adolescents with use temporal progression of dependence China, 575-582, 1305-1315
disorders, 58-69 (S) symptoms, 543-554 and cigarette smoking, US, 861-869
cost of outpatient treatment for Community intervention, underage classic texts, 11 1—1 12 (BR)
adolescents, 84—97 (S) drinking, Mexico, 1205-1214 community pharmacy services,
dependence in young adults, Community pharmacy services for drug 1405-1411
Australia, 187-194 misusers, Scotland, 1405-1411 ERIT-Italia, federation for professionals
Dutch policy evaluated, 119-120 Community reinforcement approach to working in the field of,
(N&N) treatment, 762-763 (BR) 1365-1367
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 1629-1634
Subject Index 1631]
estimating prevalence, 359-360 (L) ERIT-Italia, federation for professionals France
mortality working in the field of drug buprenorphine abuse by intravenous
after seeking treatment, 39-47 abuse, 1365-1367 injection, 1355 (L)
recent contact with health and Estonia, smoking patterns, 871-876 methadone-related overdoses
social services, 1517-1522 Ethanol see Alcohol 1221-122223 3 (L)
and motherhood, 1227 (BR) Ethical issues ypiate and opioid poisonings,
prevention, 67—7 3, 478-481 (E), addictions research, 229-2 30 (1 11229955 -1304
1228-1229 (BR) prevention and treatment
Scotland, 1405-1411, 1517-1522 Gambling
social cost, Spain, 1145 1153 European alcohol policies, global emotion, implicit decision making and
South African Community ramifications, 615-617 (E) persistence, 598—599 (L)
Epidemiology Network on Drug European Comparative Alcohol Study pathways model, 487-499
Use (SACENDU), 969-976 (ECAS) Project Reports, 238 research, potential conflict of interest,
see also Initiation, drug use; specific (BR) 600-601 (L)
drugs/drug groups European Monitoring Centre for Druuggs s|l ot-machines, 237 (BR
Drug policies, 365-366 (BR) and Drug Addiction (EMCDDA) and smoking, 745-753
1479-1480 (BR) statistics, 1359 (N&N and treatment, 1076—1(
Britain, 233 (N & N), 240-241 (BR) Evolutionary approaches, 37 5-379 | Gaming Gambling
cross-cultural, and program 470-472 (C) Gamma-hydroxy-butyric acid (GHB),
development, 161 7 (BR) alcohol consumption, 381-388 letection and pharmacology,
frontier regions, France, 1221-1223 401-413, 415-425 1229-1230 (BR)
(L) biopsychosociality and, 447-458 Gat way hypothesis, 1482 (BR),
Office for Drug Control and Crime brain emotional systems, 459-469 1493-1503, 1505-1510 (C)
Prevention (ODCCP) 1358 psychotropic substance-seeking men, anabolic steroid use and
(N&N) pathology or adaptation associated health risks, 195-203
UN conventions, penal aspects, 389-400 Gender
1482-1483 (BR) relevance for therapy, +7 3-474 and alcohol, 877-889, 1025-1036
US, 647 (E), 611 (N & N), 647-662, SPFit theory of drug use disorders European adolescent substance use,
653-664 (C), 1478-1479 (BR) 427-445 329
Drug tourism, 1355 (L) Expectancy model and smoking
Drug Use Calculator, 121 (N & N) alcohol consumption, 599-600 Women
Dual dependence, 169-178 717-726 General Medical Council (GMC), on
DUI see Driving under the influence smoking, 87-93 ommercialized detoxification,
Extinction research and theory, in cue 475-477 (E)
ECAS see European Comparative Alcohol General practice
Study ) depressed chronic benzodiazepine
Economic perspectives users, psychometric evaluation
analysis of adolescent alcohol use, Family during a discontinuation
1573 1582 childhood and adolescent antec program, 33 7 >TAt )
cannabis of substance use in adultho smcking cessation, 595-597
cost of treatment, 84—97 (S) 8 33-844 see also Doctors; Outpatient treatment
gateway effect, 1505 (C) interventions and services Genital self-mutilation, amphetamine
Ecstacy, 920-921 (BR) 1361-1363 (E) use and, 1215-1218
impact of regular use on memory liability in smoking persistence Germany
function, 1523-1529 nicotine dependence, 10 70 al l, 115-116 (BR), 1077-1078
tablet content: implications for study motherhood and drug misuse, 122 BR)
of long-term effects, 1531-1536 alcoholism and somatic comorbidity
tablet testing, 231-232 (L) role in adolescent substance umong homeless, Mannheim,
Educational attainment and drinking 329-336, 1537-1 1593-1600
behaviour, 717-726 role in development of al ust IFT newsletter, 1358 (N & N)
EMCDDA see European Monitoring disorders, 217-226 syphilis infection among drug addicts,
Centre for Drugs and Drug Fathering 601-602 (L)
Addiction alcohol use disorders and GHB see Gamma-hydroxy-butyric
Emotion. implicit decision making and substance abuse ana, 1109-1115 acid
persistence at gaming, 598-599 1117-1122 (C) Glatt, Max (obituary) 1224 1226
(L) Finland GMC sec General fedical Council
Emotional systems, brain, 459-469 adolescent part-time work and heavy
Employment, and drinking, 311-318, drinking, 311-318 Hair morphine concentrations,
717-726 deaths from alcohol poisonings, 929 977-984
Equador, prevention of alcohol problems, (E) Health Education Board for Scotland
120 (N & N) effects of alcohol policy liberalization, (HEBS), 1358 (N & N)
Erectile dysfunction in substance abusers 701-706 Health and retirement study (HRS),
treated with sildenafil Fischman, Marian Weinbaum (obituary), excess alcohol consumption and
1473-1474 603-604 outcomes, 301-310
2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 1629-1634
1632 Subject Index
Hepatitis Initiation, drug use smoking cessation in, 1317-1328
hepatitis B vaccination, drug injectors, China, 575-582 Mexico
985-992. 1611-1614 (L) gateway hypothesis, 1482 (BR), alcohol in Mexico City, 1617-1618
hepatitis C, 1230-1231 (BR), 1493-1503, 1505-1510 (C) (BR)
1289-1294 injection, 1003-1009 cross-border drinking, 1195-1203,
knowledge and risk behaviour, drug in prison, England and Wales, 1205-1214
injectors, 1277-1287, 1551-1560 Mixed drug use, 39-47, 1269-1275,
1289-1294 Injectors 1295-1304
Heroin buprenorphine abuse, 1355 (L) Monoamine oxidase B inhibitor
classic texts, McCoy: The Politics of hepatitis B vaccination, 985-992, (lazabemide), aid to smoking
Heroin in South-east Asia, 1611-1614 (L) cessation, 1347 1354
1615-1616 (BR) initiation, 1003-1009 Moser, Joy (obituary), 759-760
factors associated with abstinence, risk behaviours, 765-767 (BR), Motherhood, and drug misuse, 1227
lapse or relapse to use after 1011-1024, 1277- 122O8/7, (BR)
residential treatment: protective 1289-1294 Motivational interview, evaluation,
effect of coping responses, International Harm Reduction 1329-1337
1259-1267 Association, Brazil conference, Naltrexone maintenance treatment in
no positive tests for syphilis, 1488-1489 (N & N) opioid dependence, 1241-1249
north-eastern Italy, 104-105 International Society of Addiction Needle/syringe exchange
(L) Journal Editors (ISAJE), 372 brief alcohol interventions (BRAINE),
price, purity, availability and use, (N&N) 691-700
Australia, 179-186 Interviews, 1239 (E) UK survey, 845-850
suicide among users: rates, risk factors Enoch Gordis, 141-151 Neuro-evolutionary perspective.
and methods, 1 38 3—1 394 Ireland, alcohol policy, 1621 (N & N) 459-469
see also Drug dependence; Drug Italy Nicotine see Smoking; Smoking
misuse; Heroin overdose; ERIT-Italia, federation for professionals cessation: Tobacco industry
Injectors; Methadone working in the field of drug Nicotine replacement therapy (NRT),
maintenance: Opiate/opioid abuse, 1 365-1367 efficacy of prescription and over-
dependence: Opiate/opioid no positive tests for syphilis among the-counter, 505-516
detoxification heroin users, 104—105 (L) Nimodipine in opiate detoxification
Heroin overdose 819-824
falling death rates in Australia, 1358 Japan, metamphetamine use, 809-817 Norway
(N&N) Jellinek Memorial Award, 1234 (N & N) ECAS Project Reports on alcohol
hair morphine concentrations of fatal Journals consumption and drinking
cases and living users, 977-984 Journal of Teaching in the Addictions, patterns, 23 239 (BR)
important consequences of, 927-928 372 (N&N) high dose buprenorphine in opiate
(E) on-line, 610 (N & N) dependents waiting for
non-fatal role in raising profile of research medication-assisted
effect of frequency and route of ethics, 229-230 (L) rehabilitation, Oslo, 53 3-542
administration, 319-327 Juvenile offenders, treating cannabis use
morbidity associated with, 963-967 disorders in, 35—45 (S) Obituaries
witnessing, experiences of young Lazabemide, aid to smoking cessation, Marian Weinbaum Fischman
injectors, San Francisco, 1347-1354 60 3-604
1511-1516 Life-history theory and risky drinking, Max Glatt, 122
HIV/AIDS, injectors’ awareness and risk 401-413 Joy Moser, 759-760
behaviour, 765-767 (BR), Lung function, tobacco and cannabis Occupational attainment and drinking
1011-1024, 1277-1287 effects in young adults, behaviour, 717-726
Holland 1055-1061 Offenders
cannabis policy evaluated, 119-120 addicted, British policy and practice
(N&N) Marajuana see Cannabis 365 (BR)
overdose mortality, methadone Marajuana Treatment Project (MTP), drug use initiation in prison,
treatment, 993 1001 109-124 (S) 1551-1560
Homeless, alcoholism and somatic MDMA see Ecstacy juvenile, treating cannabis use
comorbidity among, Mannheim, Memory function, impact of regular disorders, 35—45 (S)
Germany, 1593-1600 ecstacy use, 1523-1529 Office for Drug Control and Crime
HRS see Health and retirement study Metamphetamine Prevention (ODCCP), 1358 (N &
Hypothalamic—pituitary—thyroid (HPT) Asian Pacific region, 771-772 (E) N)
axis dysregulation in alcoholism, and genital self-mutilation, On-line journals, 610 (N & N)
1369-1381 1215-1218 Opiate/opioid dependence
Japan, 809-817 @,-adrenergic agonists in withdrawal,
Illicit Drug Reporting System (IDRS), Thailand, 771-772 (E), 801 SOS 49-58
heroin use, Australia, 179-186 Methadone maintenance buprenorphine therapy, 533 542.
Impaired Control Scale, in alcohol deaths, 371 (N & N), 993 1OO1, 1395 1404
treatment, 1 339-1346 1221-1223 (L) history, 608 609 (BR)
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 1629 1634
Subject Index 1633
naltrexone maintenance treatment, Protective effect of coping responses, symptom exacerbation among treated
1241-1249 after residential treatment for substance abusers, 75-85
poisoning trends, north-east Paris and heroin use, 1259-1267 Road traffic accidents, 909-914,
suburbs, 1295-1304 Psychological approaches 1439-1448
prescribed diamorphine, UK cannabis use and adjustment, Route of administration
1155-1161 1123-1135 metamphetamine, Japan, 809-817
see also Drug dependence; Drug clinical psychology, modular course, non-fatal heroin overdose, 319-327
misuse; Heroin; Heroin overdose; 1481-1482 (BR) Russia, alcohol-related mortality,
Injectors; Methadone evolution meets biopsychosociality 1413-1425
maintenance; Opiate/opioid 447-458
detoxification excessive appetites view of addiction SACENDU see South African Community
Opiate/opioid detoxification, 59-65 113 (BR) Epidemiology Network on Drug
1395-1404 gender differences in determinants of | se
dangers, 475-477 (E), 1071-1073 smoking, 733-743 Schizophrenia, smoking cessation,
nimodipine, 819-824 Public health perspective, alcohol 785-793. 795-800 (C)
Outpatient treatment 633-645, 929 (E)
benzodiazepine dependence 851-859 (N&N) community pharmacy services for
cannabis users, 46-57 (S), 70-83 (S), Public—private partnerships drug misusers, 1405-1411
84-97 (S) ‘third party’ threats to research Health Education Board for Scotland
substance users, 347-356 integrity, 1251-1255 HEBS), 1358 (N & N)
see also Doctors; General practice 1256-1258 (C) ethadone-related deaths, 371 (N &
tobacco dependence reduction N
Parental influences see Family 951-955, 957-962 (¢ recent contact with health and social
Fathering; Motherhood see also Conflict of interest; Tob services before fatal drug
Part-time work and heavy drinking, industry overdoses, 1517-1522
Finland, 311-318 SDS see Severity of Dependence Scale
Partnership characteristics, HIV risk Questionnaires Sedative use and misuse, United States,
behavioursi n African-American Alcohol Urge, 1465-1472 555-562
injector networks, 1011 1024 Benzodiazepine Withdrawal Symptom Self-interviewing survey, metaphetamine
Passive smoking and cancer, 1487 937-345 use, 801-808
(N & N) Self-mutilation, genital, amphetamine
Paternal influences see Fathering Rapid opioid detoxificatic use and, 1215-1218
Pathways model, problem and dangers, 1071-1073 Self-perceived survival ability and
pathological gambling, 487-499 death following, +75 reproductive fitness (SPFit)
Peer ratings of quality, citation counts Relapse theory of drug use disorders,
and, 501-504 heroin use after residential t1 427-445
Pharmacological interventions for 259-1267 sell-report
substance misuse and rec overy in addictions, 36 cannabis use, 98-108 (S)
by British NHS treatment services neuroevolutionary perspective,
59-65 Relapse prevention 159-469
see also specific int smoking, 1093-1108 ty of Dependence Scale (SDS),
Pharmacy services, drug misusers, vs. 12-Step altercare progr cocaine, 727-731
Scotland, 1405-1411 for substance abusers, f Sex Gender
Photo history series, 1O87—1092 Research Society on Alcoholism Sildenafil, erectile dystunction in
Poland challenging traditional +8 3-486 substance abusers treated with,
treatment divisions, 1487 Risk behaviours
N&N) anabolic steroid use amor
Poly-drug use, 39-47 195 03
1295-1304 brief prevention for adolesce« idolescents
Pregnancy 563-574 and alcohol use: onset, persistence
maternal cannabis use and childhood injectors, 765-76 and trajectories, 517-531
cancer, 2443 (I 1277-1287 beyond the U-curve: relationship
and smoking, politics of life-history theory between sport and alcohol,
protection, 237-23 101-413 cigarette and cannabis use,
Prevention programmes recreational drug culture (SONAR 707-716. 1607-1611 (L)
alcohol and substance abuse, 607 Project), 363-364 (BR antismoking campaign, 1233 (N & N)
(BR), 920 (BR) Risk factors attention to signals of reward and
community, underage drinking, compliance with hepatitis B threat, Stroop paradigm,
Mexico, 1205-1214 vaccination in heroin users 1163-1170
drug misuse, 67—7 3, 478-481 (E), 985-992 beliefs and risk-awareness in
1228-1229 (BR metamphetamine use, Thai youth, university students, international
risk-taking behaviour, 563-574 801-808 comparison, 1561-1571
see also Relapse prevention smoking and Alzheimer's disease, familial liability and the role of
Project MATCH, 1477-1478 (BR) 15-28 nicotine dependence, 1063-1070
2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 1629-1634
1634 Subject Index
gender differences, 733-743 ‘Stages of change’ (L), 227-229 (L), 756-758 (L),
illicit drug users, US, 861-869 assessment of smokers, 1 171- 1359-1360 (N&N)
increased severity of gambling 1182 see also Public—private partnerships
problems, 745-753 substance abuse treatment and, 12-Step aftercare programs (TSF) vs.
passive smoking and cancer, 1487 (N 607-608 (BR) relapse prevention, for substance
& N) Stroke, alcohol consumption and, abusers, 677-689
patterns, Estonia, 871-876 102-104 (L), 230-231 (L)
and pregnancy, politics of fetal Stroop paradigm, smoking and attention Ultra-rapid opiate detoxification (UROD)
protection, 237—238 (BR) to signals of reward and threat, see Rapid opioid detoxification
relapse proneness, 1093-1108 1163-1170 United Kingdom (UK) see Britain
risk factor for Alzheimer's disease, Substance abuse United Nations (UN)
15-28 childhood and adolescent antecedents drug conventions, penal aspects,
‘stages of change’ assessment, of, in adulthood, 8 33-844 1482-1483 (BR)
1171-1182 and fathering, 1109-1115, Office for Drug Control and Crime
tobacco and cannabis, effects on lung 1117-1122 (C) Prevention (ODCCP), 1358 (N &
function in young adults, parental, as modifier of adolescent, N)
1055-1061 risk, 1537-1550 United States (US)
urge and expectation, 87—9 3 SPFit theory of disorders, 427-445 American Medical Research Society
see also Smoking cessation; Tobacco Substance abuse intervention on Alcoholism (AMSA), 483-486
industry adolescent, 920 (BR) comparison of alcohol use between
Smoking cessation motivational interview in psychiatric American and Canadian college
assessing scientific base fox, in-patient services, 1 329-1337 students, 1583-1592
1480-1481 (BR) pharmacological, British NHS hepatitis knowledge and risk, injectors
daily smokers, Malmé, Sweden, treatment services, 59-65 in three cities 1277-1287
205-215 prevention, rehabilitation and systems illicit drug policies, 647 (E), 611 (N &
GP desktop resource, 595-597 change strategies, 764-765 (BR) N), 647 662, 653-664 (C),
Health Education Board for Scotland relapse prevention vs., 1 2-Step 1478 1479 (BR)
(HEBS), 1358 (N & N) aftercare programs, 677-689 National Comorbidity Survey, cocaine
lazabemide, as aid to, 1347-1354 risk factors for symptom exacerbation, dependence symptoms, 543-554
in methadone maintenance, 75-85 sedative use and misuse, 55 562
1317-1328 role of functional social support, tobacco industry, 1227 (BR)
nicotine replacement therapy (NRT), 347-356 treatment, early pioneers and
efficacy of prescription and over- screening test (ASSIST): development, institutions, 1O87—1092
the-counter, 505-516 reliability and feasibility, rine testing
in schizophrenia, 785-793, 795-800 1183-1194 cannabis, 98—108 (S)
(C) sildenafil treatment of erectile metamphetamine, 801-808
services, UK, 234 (N & N) dysfunction, 1473-1474
Video game playing, measuring problem
Social cost of illegal drug consumption, and stages of change, 607—608 (BR)
in adolescents, 1601-1606
Spain, 1145-1153 Substance Abuse and Mental Health
Violence, alcohol-related, Australia,
Social integration, alcohol consumption Services Administration
1622 (N&N)
and all-cause mortality, 29-38, (SAMHSA), 121 (N& N)
915-916 {L) Suicide among heroin users: rates, risk Withdrawal symptoms
Social networks, and effect of Alcoholics factors and methods, 1 383-1394 3enzodiazepine Withdrawal Symptom
Anonymous, 891—900 Sweden Questionnaire, 337-345
Social support in treatment retention overserving study, Stockholm, cannabis users, 621—632, 754-756
and outcomes among outpatient 901-907 (L), 916-917 (L)
adult substance abusers, smoking cessation among daily Women
347-356 smokers, Malm6, 205-215 and alcohol, 763—764 (BR)
South African Community Epidemiology Symptom exacerbation among treated handbook of addiction treatment for
Network on Drug Use substance abusers, 75-85 1619-1620 (BR)
(SACENDU): description, Syphilis in drug users see also Gender: Pregnancy
findings and policy implications, north-eastern Italy, 104—105 (L)
969-976 Western Germany, 601—602 (L) Young adults
Spain Syringe exchange see Needle/syringe alcohol consumption see under Alcohol
social cost of illegal drug exchange cannabis dependence, Australia
consumption, 1145-1153 187-194
youth, leisure and alcohol Thailand, 233 (N & N) smoking beliefs and risk-awareness in
consumption, 1232 (N & N) development of alcohol use disorders, university students, international
SPFit see Self-perceived survival ability 217-226 comparison, 1561] 157]
and reproductive fitness theory metamphetamine use, 771] 772 (E). tobacco and cannabis effects on lung
Sport and alcchol, cigarette and 801-808 function, 1055 1061
cannabis use in adolescents, Tobacco industry, 114-115 (BR), Young people see Family; Prevention
beyond the U-curve, 707-716, 918-919 (BR), 1227 (BR) programmes; specific substances
i607-1611 (L) conflict of interest, 1—5 (E), 95 102 and addiction problems
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs tion, 97, 1629 1634